Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

266.44
-1.6050-0.60%
Volume:1.14M
Turnover:305.30M
Market Cap:641.92B
PE:30.85
High:267.77
Open:266.96
Low:265.57
Close:268.04
52wk High:276.47
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.82
T/O Rate:0.05%
Dividend:5.24
Dividend Rate:1.97%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.55
PE(LYR):24.15

Loading ...

Johnson & Johnson announces leadership change in Innovative Medicine

TIPRANKS
·
Aug 04

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

TIPRANKS
·
Aug 04

Johnson & Johnson Names Tom Cavanaugh EVP, Worldwide Chairman of Innovative Medicine as Taubert Retires

Reuters
·
Aug 04

J&J - Tom Cavanaugh to Succeed Jennifer Taubert as Evp, Worldwide Chairman Innovative Medicine

THOMSON REUTERS
·
Aug 04

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 04

Johnson & Johnson is Maintained at Overweight by Wells Fargo

Dow Jones
·
Aug 03

Achieve Life Sciences Names Ronald Dadino SVP of CMC and Supply Chain

Reuters
·
Aug 03

Lipocine Appoints Ex-J&J Executive Michael Grissinger to Board

Reuters
·
Aug 03

Eli Lilly Stock Leads 3 Pharma Picks As Merger Talk Shakes Big Drugmakers

Simply Wall St.
·
Aug 03

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

TIPRANKS
·
Aug 03

Perrigo Co. PLC Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 01

The Week in Breakingviews: Wall Street Rainstorms

Reuters
·
Aug 01

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Benzinga
·
Aug 01

Stryker Beats Quarterly Estimates on Strong Demand for Medical Devices

Reuters
·
Jul 31

Johnson & Johnson Stock (JNJ) Moved Down by 3.49% on Jul 30: Key Drivers Unveiled

TradingKey
·
Jul 31

Movement Alert|Johnson & Johnson Falls 3.23% in Regular Trading, $2.58 Billion Sail Biomedicines Acquisition Option Sparks Short-Term Earnings Dilution Concerns

Market Focus
·
Jul 30

Sector Update: Healthcare

MT Newswires Live
·
Jul 30

Johnson & Johnson’s Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) Receives U.S. FDA Priority Review as Potential First-in-Class Egfr- and Met-Targeted Subcutaneous Treatment for Advanced Head and Neck Cancer

THOMSON REUTERS
·
Jul 30

PRESS Digest -Wall Street Journal - July 30

Reuters
·
Jul 30

Dow Jones Top Company Headlines at 9 PM ET: Samsung's Chip Earnings Push Net Profit to Record | Microsoft ...

Dow Jones
·
Jul 30